Celgene submits NDA for multiple myeloma, forges personalized medicine collaboration

Celgene (NASDAQ:CELG) has submitted a new drug application to the U.S. Food and Drug Administration for pomalidomide, a drug designed for multiple myeloma that does not respond to therapies. Since the…
Read the full story: MedCity News